Regulus Therapeutics Inc. (NASDAQ:RGLS) CEO Joseph P. Hagan Sells 115,290 Shares

Regulus Therapeutics Inc. (NASDAQ:RGLS) CEO Joseph P. Hagan sold 115,290 shares of the company’s stock in a transaction that occurred on Monday, January 13th. The shares were sold at an average price of $1.26, for a total transaction of $145,265.40. Following the completion of the sale, the chief executive officer now directly owns 222,572 shares of the company’s stock, valued at $280,440.72. The trade was a 34.12 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link.

Regulus Therapeutics Price Performance

RGLS stock traded up $0.05 during trading hours on Wednesday, reaching $1.27. 283,082 shares of the stock were exchanged, compared to its average volume of 348,120. The firm’s 50-day moving average is $1.53 and its 200-day moving average is $1.59. Regulus Therapeutics Inc. has a 12 month low of $1.08 and a 12 month high of $3.79. The company has a market cap of $83.19 million, a price-to-earnings ratio of -1.19 and a beta of 1.60.

Regulus Therapeutics (NASDAQ:RGLS) last posted its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.03). As a group, equities research analysts forecast that Regulus Therapeutics Inc. will post -0.88 earnings per share for the current year.

Institutional Trading of Regulus Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. JPMorgan Chase & Co. boosted its holdings in Regulus Therapeutics by 193.4% during the third quarter. JPMorgan Chase & Co. now owns 78,972 shares of the biopharmaceutical company’s stock worth $124,000 after purchasing an additional 52,059 shares during the last quarter. Barclays PLC lifted its position in Regulus Therapeutics by 285.2% during the 3rd quarter. Barclays PLC now owns 84,477 shares of the biopharmaceutical company’s stock worth $132,000 after buying an additional 62,549 shares in the last quarter. Jane Street Group LLC acquired a new position in shares of Regulus Therapeutics during the 3rd quarter worth about $46,000. State Street Corp grew its holdings in shares of Regulus Therapeutics by 3.5% in the 3rd quarter. State Street Corp now owns 1,000,998 shares of the biopharmaceutical company’s stock valued at $1,572,000 after acquiring an additional 33,496 shares in the last quarter. Finally, Point72 Asset Management L.P. acquired a new stake in shares of Regulus Therapeutics in the third quarter valued at about $1,403,000. 92.38% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several brokerages recently commented on RGLS. HC Wainwright reaffirmed a “buy” rating and set a $10.00 price objective on shares of Regulus Therapeutics in a research note on Monday, November 11th. StockNews.com raised Regulus Therapeutics to a “sell” rating in a research report on Tuesday, September 17th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat, Regulus Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $10.80.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.